Oarsman Capital, Inc. Bio Affinity Technologies, Inc. Transaction History
Oarsman Capital, Inc.
- $562 Million
- Q4 2024
A detailed history of Oarsman Capital, Inc. transactions in Bio Affinity Technologies, Inc. stock. As of the latest transaction made, Oarsman Capital, Inc. holds 2,448 shares of BIAF stock, worth $1,933. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,448Holding current value
$1,933% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding BIAF
# of Institutions
17Shares Held
536KCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA261KShares$206,0860.0% of portfolio
-
Geode Capital Management, LLC Boston, MA99.6KShares$78,6450.0% of portfolio
-
Sheaff Brock Investment Advisors, LLC46.3KShares$36,5800.0% of portfolio
-
Captrust Financial Advisors Raleigh, NC27.9KShares$22,0290.0% of portfolio
-
State Street Corp Boston, MA17.6KShares$13,9040.0% of portfolio
About bioAffinity Technologies, Inc.
- Ticker BIAF
- Exchange
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 2,727,580
- Market Cap $2.15M
- Description
- bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is b...